2026-05-17T00:20:35Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/231692024-11-28T23:26:03Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Roman-Rodriguez, Miguel
author
Kaplan, Alan
2024-09-18T06:42:08Z
2024-09-18T06:42:08Z
2021
Roman-Rodriguez M, Kaplan A. GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap. Int J Chronic Obstr Pulm Dis. 2021;16:1709-15.
10.2147/COPD.S300902
1178-2005
International Journal of Chronic Obstructive Pulmonary Disease
https://hdl.handle.net/20.500.13003/19610
34163155
L2007625886
2-s2.0-85108723989
https://hdl.handle.net/20.500.12105/23169
662308400001
In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may [...] coexist in an individual patient. If a concurrent diagnosis of asthma is suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non-pharmacological approaches may also be needed for their COPD. What does this mean for the treating physician? In this review, we explore the implications of this new guidance on treating patients with chronic obstructive pulmonary disease, arguing for a personalized approach to treatment.
eng
COPD
Asthma
Asthma-COPD overlap
Inhaled corticosteroid
Bronchodilator
GOLD 2021 Strategy Report: Implications for Asthma-COPD Overlap
research article